Table 1 Patient demographics of 86 patients underwent CRS+HIPEC
Characteristics | Total (n=86) |
|---|---|
Age at operation (y, mean ± SD) (range) | 55.6 ± 11.7 (27–74) |
Gender (%) | |
 Male | 45 (52.3) |
 Female | 41 (47.7) |
Preoperative chemotherapy (%) | 41 (51.2) |
Presentation of PM (%) | |
 Synchronous | 52 (60.5) |
 Metachronous | 34 (39.5) |
Site of original (%) | |
 Colon | 63 (73.3) |
 Rectum | 23 (26.7) |
Preoperative CEA level (ng, mean ± SD) (range) | 33.4 ± 65.2 (0.6–291.7) |
Preoperative CA19–9 level (ng, mean ± SD) (range) | 68.3 ± 87.7 (0.7–363.5) |
Histology (%) | |
 Adenocarcinoma | 55 (64.0) |
 Mucinous | 31 (36.0) |
Liver metastases | 17 (19.8) |
HIPEC regimen | 5 (6.6) |
 Lobaplatin+Oxaliplatin+Raltitrexed | 40 (46.5) |
 Oxaliplatin+Raltitrexed | 46 (53.5) |
PCI score | 11.2 ± 5.7 (2–24) |
Operation time (min, mean ± SD) (range) | 264.0 ± 70.3 (145–510) |
Estimated blood loss (ml, mean ± SD) (range) | 121.4 ± 107.8 (20–500) |
Presence of ascites | 37 (43.0) |
CC score | |
 CC 0–1 | 54 (62.8) |
 CC 2–3 | 32 (37.2) |
Postoperative Complications (grade 1–4) (%) | 41 (47.7) |
Postoperative Complications (grade 3–4) (%) | 22 (25.6) |
Mortality (%) | 0 (0) |
Total hospital stay (day, mean ± SD) (range) | 15.4 ± 6.0 (7–44) |